Victoria Cogger

Victoria Cogger is  the Director of the ANZAC Research Institute at Concord Hospital, a biomedical research institute focussed on integrating the highest quality innovative research in the basic sciences with clinical and population health. 

Victoria leads a multidisciplinary research team focussed on understanding the biology of the liver relating to ageing and disease, and translating this knowledge to develop targeted therapies for the treatment and prevention of these diseases. She is co-founder, scientific adviser and a shareholder of EndoAxiom, a company leading the development of nanomedicines for use in people. Its lead product is oral insulin for the treatment of diabetes – the culmination of 20 years of research collaboration by Professor Cogger and colleagues.